bluejaytx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $242.24MM
Bluejay Therapeutics is a biopharmaceutical company that aims to develop treatments for chronic viral infections and liver disease, particularly chronic hepatitis B virus (HBV) infections. The company has a mission to reduce hepatitis B surface antigen (HBsAg) levels with the goal of restoring antiviral immunity for patients. Bluejay Therapeutics was founded in 2019 by Dr. Keting Chu and is headquartered in San Mateo, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/09/2024 | Series C | $180.86MM | $xx.xx | $371.77MM | Arkin Bio Ventures, Frazier Life Sciences, Hbm Healthcare Investments, Novo Holdings, Octagon Capital, Ra Capital Management, Rivervest Venture Partners, T. Rowe Price, Unicorn Capital, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
27,711,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arkin Bio Ventures, Frazier Life Sciences, Hbm Healthcare Investments, Novo Holdings, Octagon Capital, Ra Capital Management, Rivervest Venture Partners, T. Rowe Price, Unicorn Capital, Wellington Management
|
||||||
05/09/2024 | Series C-1 | $1.14MM | $xx.xx | $371.77MM | Arkin Bio Ventures, Frazier Life Sciences, Hbm Healthcare Investments, Novo Holdings, Octagon Capital, Ra Capital Management, Rivervest Venture Partners, T. Rowe Price, Unicorn Capital, Wellington Management | |
Price per Share
$xx.xx
Shares Outstanding
173,980
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arkin Bio Ventures, Frazier Life Sciences, Hbm Healthcare Investments, Novo Holdings, Octagon Capital, Ra Capital Management, Rivervest Venture Partners, T. Rowe Price, Unicorn Capital, Wellington Management
|
||||||
08/16/2022 | Series B | $41MM | $xx.xx | $125.7MM | Arkin Bio Ventures, Innopinnacle International, Octagon Capital, Rivervest Venture Partners, Synergenics Llc, Yonjin Capital | |
Price per Share
$xx.xx
Shares Outstanding
9,764,218
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arkin Bio Ventures, Innopinnacle International, Octagon Capital, Rivervest Venture Partners, Synergenics Llc, Yonjin Capital
|
||||||
06/10/2021 | Series A | $15.87MM | $xx.xx | $48.1MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,293,097
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
06/10/2021 | Series A-1 | $3.37MM | $xx.xx | $48.1MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
910,134
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|